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Background: Suboptimal utilisation of pharmacotherapy, 
non-adherence to prescribed treatment, and a lack of 
monitoring all contribute to poor blood (BP) pressure 
control in patients with hypertension. 
Objective: The objective of this study was to evaluate the 
implementation of a pharmacist-led hypertension 
management service in terms of processes, outcomes, 
and methodological challenges. 
Method: A prospective, controlled study was undertaken 
within the Australian primary care setting. Community 
pharmacists were recruited to one of three study groups: 
Group A (Control – usual care), Group B (Intervention), or 
Group C (Short Intervention). Pharmacists in Groups B 
and C delivered a service comprising screening and 
monitoring of BP, as well as addressing poor BP control 
through therapeutic adjustment and adherence strategies. 
Pharmacists in Group C delivered the shortened version of 
the service. 
Results: Significant changes to key outcome measures 
were observed in Group C: reduction in systolic and 
diastolic BPs at the 3-month visit (P<0.01 and P<0.01, 
respectively), improvement in medication adherence 
scores (P=0.01), and a slight improvement in quality of life 
(EQ-5D-3L Index) scores (P=0.91). There were no 
significant changes in Group B (the full intervention), and 
no differences in comparison to Group A (usual care). 
Pharmacists fed-back that patient recruitment was a key 
barrier to service implementation, highlighting the 
methodological implications of screening. 
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Conclusion: A collaborative, pharmacist-led hypertension 
management service can help monitor BP, improve 
medication adherence, and optimise therapy in a step-
wise approach. However, blood pressure screening can 
effect behaviour change in patients, presenting 
methodological challenges in the evaluation of services in 
this context. 
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There is a need for targeted services in chronic 
disease management, particularly in hypertension 
where up to 67.5% of people are reported to have 
inadequate blood pressure (BP) control.
1
 Clinical 
inertia, non-adherence by patients, and a lack of 
monitoring underpin poor BP control.
2-4
 Here, an 
opportunity exists for a multi-faceted, collaborative 
approach involving the community pharmacist and 
GP to optimise hypertension management.
5
 In the 
Australian primary care setting, a number of studies 
have shown that pharmacist-led interventions can 
rationalise medicines use in patients
6,7
, improve 
clinicians’ prescribing of evidence-based therapies 
in cardiovascular disease
7-9
, and improve patient 
self-management as well as clinical outcomes.
10,11
  
In regard to the management of hypertension, 
previous studies have demonstrated the positive 
impact that pharmacists can have on a range of 
outcomes. Even dating back to the 1990s, studies 
have shown that community pharmacist-led 
services comprising patient education and blood 
pressure monitoring (including the use home blood 
pressure readings obtained from monitors that 
wirelessly transmit information to the pharmacy) can 
improve patient knowledge about hypertension, 
significantly decrease mean blood pressure, 
improve blood pressure control in those not at 
treatment targets, and rationalise the use of 
antihypertensive medication.
12-15
 A Cochrane review 
also reports the positive outcomes from pharmacist-
led care, with the majority of controlled trials 
associated with improved blood pressure control.
16
 
Even those studies that have focused on patient 
self-management (e.g., self-monitoring of BP) have 
shown that additional support from health 
professionals may enhance the BP lowering effect 
of any intervention.
17
 Pharmacy practice has, of 
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course, evolved in recent times, comprising more 
specialised roles and an expanded scope of 
practice. This has been highlighted by the 
RxACTION trial (i.e., the Rural Alberta Clinical Trial 
in Optimizing Hypertension).
18
 which evaluated the 
impact of enhanced pharmacist care on the 
management of patients with hypertension; this 
enhanced care involved pharmacists taking a more 
active role and independently prescribing 
antihypertensive medication. The study showed that 
the enhanced care resulted in significantly larger 
reductions in both systolic and diastolic blood 
pressure, with patients twice as likely to reach their 
recommended blood-pressure targets, compared to 
usual care. Although this type of expanded care is 
not yet legislated in Australia, pilot studies have also 
demonstrated the potential for pharmacist 
prescribing in hypertension management, 
suggesting that credentialed pharmacists are able 
to make appropriate therapeutic decisions.
19
 
In delivering such interventions, it is important to 
recognise that the management of hypertension is 
relatively complex, comprising screening and 
monitoring of blood pressure, addressing adherence 
barriers, and reviewing pharmacotherapy.
20,21
 It is 
these aspects of hypertension management that 
Australian community pharmacists need to currently 
focus on, in preparation for future expanded care 
services.
22,23
 Therefore, the aim of this paper is to 
report on the lessons learned from a pilot study of a 
pharmacist-led intervention (hypertension 
management service) in Australian primary care. 
Specifically, the objectives of this paper are to: 1) 
describe the key outcomes following delivery of the 
intervention; 2) report pharmacists’ feedback 
regarding service implementation and any 
methodological challenges; and 3) discuss the 




Study Design - Pilot study of a pharmacist-led 
intervention 
A pharmacist-led intervention was evaluated in a 3-
group prospective, controlled study commencing at 
the beginning of 2013, and concluding in mid-2014: 
initially, Group A (Control) and Group B 
(Intervention) were implemented, followed later by 
Group C (Short Intervention; Figure 1).  
Group C intervention was truncated to a period of 3-
months and comprised a convenience sample of 
pharmacists. This group was introduced later to the 
study, after the recruitment of patients to Groups A 
and B had concluded, and was based on the initial 
experience of Group B pharmacists. Group C 
represented a variation to the study protocol to 
maximise patient recruitment and to model the 
approaches used commonly in clinical practice and 
in previous hypertension studies.
24
 However 
recruitment was not aligned to guideline 
recommendations.  
 
Setting and Participants 
Community pharmacists and their patients 
(customers) were recruited to the study.  
The main study (Groups A and B) was conducted 
within pharmacies located in two Sydney 
metropolitan regions that were comparable in terms 
of socioeconomic characteristics and disease 
burden (Northern Sydney and Sutherland Medicare 
Locals, NSW, Australia). Pharmacists were 
therefore recruited based on their location in these 
regions and were cluster-randomised to Group A or 
B to minimise contamination between intervention 
and control patients.
25
 Group C was a convenience 
sample of pharmacists within both Sydney 
metropolitan and regional sites (Illawarra: n=2, 
Southern Highlands: n=1) who had not previously 
offered hypertension services. They were recruited 
using the snowball technique i.e., the researchers 
approached one pharmacist who was known to 
them from participation in previous research 
studies, and that pharmacist then approached other 
pharmacists who they thought might be interested in 
the study. 
Pharmacists within each Medicare Local region 
were initially contacted by telephone (by Project 
Officer) to gauge their interest in participating. 
Pharmacists were eligible to participate if their 
pharmacy had: 
• at least 2 pharmacists on duty to allow the 
service to proceed uninterrupted 
• a designated quiet and relatively private area for 
patient education/counselling 
• a portable Omron™ BP monitor (with a range of 
cuff sizes), which was to be calibrated (by 
Omron™) both before and during the trial to 
ensure accuracy 
• a pharmacist who could attend specialised 
training to deliver the service 
Pharmacists who were interested and eligible to 
participate were then provided an information sheet 
and consent form. All were compensated for their 
time in providing the pharmacy service and for data 
collection (Group A: AUD40 per patient; Groups B 
and C: AUD100 per patient). 
The recipients of the service were patients (i.e., the 
customers of each community pharmacist) who 
required management of their hypertension. The 
specific inclusion criteria were: 
• aged ≥18 years of age 
• able to provide written informed consent to 
participate in study  
• able to return for all follow-up visits (as per 
Figure 1) and were accessible by telephone  
• had a diagnosis of essential hypertension (new 
diagnosis or established diagnosis) which was 
not controlled and meeting criteria for therapy as 
defined by current Australian guidelines.
12
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Figure 1. Study design 
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Patients in any of the following categories were 
excluded from study participation: history of recent 
myocardial infarction, unstable congestive heart 
failure, chronic kidney disease (CKD), or poorly 
controlled asthma; pregnant female; enrolled in any 
other trial. 
The patients were initially identified from dispensed 
medication histories (dispensing program). As each 
patient presented to the pharmacy for refill 
prescriptions, the pharmacist invited them to have 
their blood pressure (BP) measured and to 
participate in the study (if eligible). The pharmacists 
performed an initial screen for poorly controlled 
hypertension by measuring the patients BP in the 
pharmacy; for confirmation, all patients in Groups A 
and B underwent repeated BP measurements (1-
week apart) prior to study enrolment, per guideline 
recommendations.
20
 In Group C, the same 
intervention was delivered but there was only 1 BP 
screening step (i.e., baseline BP was not re-
checked after 1-week) (Figure 1). Patients received 
a voucher (AUD15 for use in the pharmacy) after 
the final follow-up visit. 
Intervention 
Group A patients received usual care upon 
presentation to the pharmacist for refill 
prescriptions; i.e., supply of their medication and 
any medication counselling (Figure 1). Pharmacists 
in Group B and Group C were specially trained
9
 to 
deliver a pharmacist-led service, based on the 
Health Collaboration Model (HCM).
26
 The HCM 
describes five key barriers to treatment adherence 
that are amenable to change (i.e., regimen 
knowledge barriers; recall barriers; motivational 
barriers; side effect barriers; and access barriers) 
and which can be purposefully targeted through 
pharmacist intervention via monitoring, identification 
of barriers, engagement of patients, regular follow-
up, and provision of support to patients and 
clinicians alike. 
The intervention was delivered via face-to-face 
visits (follow-up) in the pharmacy interspersed with 
brief (5 minute) telephone follow-up by the 
pharmacist (Figure 1). In Group C the intervention 
was shortened (i.e., final face-to-face visit was 
conducted at 3-months). Each face-to-face visit 
involved BP measurement, as well as adherence 
and quality of life assessments (and/or therapeutic 
adjustment in Groups B and C) as follows:  
• screening and monitoring patients to identify 
patients with poor BP control (Figure 1) 
• applying a systematic approach to identify the 
potential cause(s) of poor control by reviewing 
patients’ medication management including 
adherence (Figure 2) 
• assessment and review of medicines for 
hypertension (agent, dosage, regimen) 
• addressing and providing support for any 
adherence issues and/or making therapeutic 
adjustment recommendations to the patient’s 
GP to optimise medicines use 
• monitoring patients at regular intervals to ensure 




All pharmacists were trained in accurate BP 
measurement (using Omron™ BP monitors), per 
the National Heart Foundation’s measurement 
protocol.
20
 The service was delivered with the 
cooperation of, and referral to, the local GP as 
appropriate; each pharmacist contacted their local 
GPs to advise them of the study and to agree on 
processes for communication and discussion 
regarding patient management (i.e., issues 
identified, actions taken, therapeutic 
recommendations). The researchers provided each 
pharmacy with document templates to help 
efficiently communicate important information to the 
GPs. This collaboration between the pharmacist 
and the GP in managing the patient’s hypertension 
was based on the principles of shared care, 
ensuring that the care provided was: patient-
centred; effectively communicated and coordinated; 
supported by both the GP and the pharmacist; and 
delivered according to best practice guidelines.
27
  
Process and outcome measures 
Purpose-designed data collection forms were 
provided to pharmacists to document service 
provision and relevant outcome measures. Process 
measures included the number of pharmacists and 
patients recruited to the study. Pharmacists’ 
interventions (adherence interventions and 
therapeutic recommendations) were initially 
categorised by the pharmacists themselves (using 
the flowchart of adherence program, Figure 2) 
during the documentation process; the nature of 
these interventions was verified by the Project 
Officer and one of the researchers, in-line with the 
categories used by the Pharmaceutical Society of 
Australia.
28
 The key clinical outcome measures 
were: BP control (change in systolic BP) and self-
reported medication adherence (using the Morisky 





, was the primary 
humanistic outcome. Comparisons in outcomes 
were made between the treatment groups at 
baseline, 3 months and 12 months (Groups A and B 
only for the latter).  
Sample size 
For the main study (Groups A and B), the target 
sample size was based on an anticipated decrease 
in systolic BP of 5 to 10mmHg (35, 36) as the 
primary outcome. Using 80% power (1-sided alpha 
of 0.05), and allowing for a patient drop-out rate of 
20%, the calculated sample size was 15 (for a 
5mmHg BP reduction) to 50 patients per group (for 
a 10mmHg BP reduction), i.e., minimum of 5 
pharmacists recruiting 3 to 10 patients each. To 
account for drop-out of pharmacists, additional 
pharmacists were recruited. For Group C, a 
purposive sample of 8 pharmacists (from 6 
pharmacies) was recruited to deliver the short 
intervention. 
Figure 2. Flowchart of adherence program based on the Health Collaboration Model (HCM) (undertaken for 14 patients) 
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 Version 19 was used to analyse the data 
pertaining to process and outcome measures, and 
included Wilcoxon signed-rank test (pre/post mean 
BPs / MMAS-8 scores), Kruskal-Wallis ANOVA 
(continuous variables, e.g., age), and Chi-square 
test for independent proportions; significance level 
was set at 0.05. EQ-5D-3L values, pertaining to 
measures of QoL, were calculated using the New 
Zealand VAS value set.
38
  
End-of-study evaluation  
At the conclusion of the study, all pharmacists 
across the three study groups were invited to 
participate in a face-to-face interview to elicit 
qualitative feedback on their experience of service 
implementation. These interviews were facilitated by 
members of the research team who were 
experienced in qualitative interview techniques, and 
who were not in direct contact with the pharmacists 
during the service implementation. A semi-
structured interview guide, modelled on that used by 
the researchers in previous studies and guided by 
the study objectives, was used to guide the 
questioning and discussion. Pharmacists’ 
responses were digitally (audio) recorded to allow 
for verbatim transcription. The transcripts were first 
analysed by an independent contracted researcher 
(not associated with the present study) using 
manual inductive coding to generate themes.
39
 
Subsequently, the research team reviewed the 
transcripts to check the reliability of the analysis and 
ensure consensus was attained regarding the 
themes (theme verification).  
A program evaluation framework (Table 1), adapted 
from Bauman and Nutbeam
40
, was then used to 
map the components of the study and challenges 
encountered during implementation of the 
intervention. This organised framework describes a 
process for evaluating intervention programs in 
healthcare, and maps out key steps including: an 
assessment of the current problem, consultation 
with stakeholders and the community, measurement 
and monitoring of intervention components, 
assessment of short-term impact, and assessment 
of the longer term outcomes. This type of logic 
model allows researchers to identify any barriers to 
the implementation and/or long-term sustainability 
of any intervention. In this study, post-service 
delivery, qualitative feedback from the pharmacists, 
a review of the study outcomes, and reflections from 




Of the 25 pharmacists initially enrolled in the study 
(8-9 pharmacists per group), 15 successfully 
recruited patients: 37.5% of pharmacists in Group 
A; 66.7% of Group B pharmacists; and 75.0% of 
Group C pharmacists (Figure 1). As expected, 
Group A pharmacists spent significantly less time 
during the first patient visit compared to Group B or 
Group C (P<0.05; Table 1). In delivering the 
service, interventions addressing medication 
adherence issues were recorded for 14 patients 
(Figure 2).   
Participant characteristics 
Thirty eight patients participated in the study (Table 
1) after excluding those lost to follow-up (i.e., unable 
to be contacted), discontinued, or with incomplete or 
invalid data (Figure 1). Patients in Group C were 
significantly younger (P=0.03) than those in Groups 
A or B (Table 2). Only 6 patients had hypertension 
without other comorbidities. Given the sample size, 
an analysis of study outcomes taking into account 
specific participant characteristics was beyond the 
scope of this pilot study. 
Outcome measure: blood pressure control 
At the screening assessment (i.e., initial BP check 
prior to patient enrolment) there was no difference 
in mean systolic BP (SBP; P=0.45) or diastolic BP 
(DBP; P=0.72) readings between Group A and 
Group B. Group C did not undertake this screening 
step. 
At the time of patient recruitment into the study 
(Baseline Visit), there was no significant difference 
in SBP or DBP between Group A and Group B 
(P=0.15 and P=0.79, respectively). However, SBP 
and DBP were significantly higher in Group C 
compared to Group B (P=0.02 and P=0.01, 
respectively) (Table 3).  
At the 3 month Visit any changes in BP (compared 
to the readings at Baseline Visit) were assessed in 
each group; there were no significant changes to 
BP within Group A patients (SBP: P=0.34, DBP: 
P=0.08). Within Group B a change in DBP was 
noted (P=0.04), but not in SBP (P=0.14). Within 
Group C, a significant change was noted in both 
SBP and DBP (P<0.01 and P=<0.01, respectively) 
(Table 3). Overall, between-group comparisons 
showed that there were no significant differences in 
the 3-month SBP (P>0.5) or DBP (P>0.5) between 
any of the three groups. 
At the follow up visit (12 months), no changes in 
SBP or DBP were noted (compared to 3 month visit) 
within either Group A (P=0.23 and P=0.69, 
respectively) or Group B (P=0.68 and P=0.87, 
respectively). Overall, there were no significant 
differences between Group A and Group B in regard 
to the 12-month SBP (P>0.5) or DBP (P>0.5). 
In terms of the absolute mean differences in SBPs 
recorded within each group from the time of the 
baseline measurement to the final visit (12 months 
for Groups A and B; 3 months for Group C), the 
largest change was observed within Group C 
(decrease of 25mmHg; P<0.01), followed by Groups 
A (22mmHg; P<0.01) and B Group (21mmHg; 
P<0.01) 
Outcome measure: medication adherence 
In terms of median adherence (MMAS-8) scores 
there were no significant differences between the 3 
study groups at any time-point (P>0.05). When 
patients were categorised according to their MMAS-
8 scores there were no significant differences in the 
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proportion of patients assessed as having low, 
medium or high medication adherence based 
between the three study groups at any time-point, 
although a slightly higher proportion of patients in 
Group C were assessed as having ‘low adherence’ 
at baseline (Table 3).  
 
Post-intervention, changes in the median adherence 
(MMAS-8) scores were observed in Groups B and 
C: 10.0% of Group B patients (n=10) and 41.2% of 
Group C patients (n=17) reported an improvement 
of 2 points or more (minimal detectable change
41
) in 
their MMAS-8 score (i.e., from baseline to 3 month 
visit). No Group A patients recorded an 
improvement of 2 points or more. At the 3 month 
Table 1. Program evaluation framework for the pilot study of a pharmacist-led hypertension management service 
Aspect of 
Evaluation 
Pre-planning phase Planning phase Implementation phase Impact and Outcomes 
Recommended 
activities and actions 
 











 Describe outcome 
measures 
 Describe specific 
strategies 
 Prepare timeline 
 Develop program 
components 
 Assess short-term and 
medium long impact of 
program 
Activities completed 










Model (HCM) (26) 
utilised 














guidelines and HCM 
(Figures 1 and 2) 
 Outcome measures 
defined, including 
process, clinical, and 
humanistic 
measures 
 Participant feedback 
to be canvassed via 
semi-structured 
qualitative interviews 
 Pharmacist training 
program developed  
(9) 
 Timeline for pilot 
study prepared 
(Figure 1) 
 Pharmacist training 
program delivered (9) 
 Service resources 
amassed (e.g., BP 
monitors) and/or 
developed (e.g., data 
recording forms) 
 Pharmacists 
supported by Project 
Officer and 
investigators with 
respect to provision of 






 Process measures 
 # pharmacists 
participating in study 
 # patients recruited 




 Clinical outcomes 
 change in systolic 
BP 





 Humanistic outcomes 
 change in QoL 
 









encountered in study 
 Absence of need 
assessment to 
identify areas of 
need / service 
gaps; over-
estimating potential 
impact of service 
 Limitation on 
pharmacists’ scope 
of practice - 
inability to 
independently 
manage patients or 
prescribe 
medication due to 
current Australian 
practice regulations 
 Not well 
established 
relationships with 
local GPs (limited 
inter-professional 
collaboration) 
 Not conceptualising 
the initial ‘screening’ 
step of the study 
(the initial BP 
checking step, prior 
to patient enrolment) 
as a key part of the 
intervention 
 Underestimating the 




variable), and it’s 
responsiveness of 
changes in patient 
behaviour 
 Complexity and 
comprehensiveness 
of study documents 
impacting on 
pharmacists ability to 
recruit patients and 
record outcome 
measures 
 Pharmacy support 
staff (e.g., pharmacy 
assistants) not 
included in training – 
unable to assist in 
patient recruitment 
 Small sample size 




planning, planning, and 
implementation phases 
reflected in outcome 
measures 
 Lack of feedback from 
GPs 
GP = general practitioner; HCM = Health Collaboration Model; BP = blood pressure; MMAS= Morisky Medication Adherence 
Scale; QoL = quality of life; # = number of participants 
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visit, a significant improvement in the median 
MMAS-8 score was only observed in Group C 
(P=0.01). At the 12 month follow-up visit, there was 
no significant change in median MMAS-8 scores 
(compared to the 3 month Visit), in either Group A 
or Group B (P=0.81 and P=0.68, respectively). 
Overall, there were no significant differences 
MMAS-8 scores between groups (P>0.5) at the 3-
month or 12-month (Group A versus Group B) visits. 
Outcome measure: quality of life 
At baseline, all patients had good QoL with no 
significant differences between groups. No changes 
were observed in EQ-5D-3L scores (Table 3).  
Outcome measure: pharmacist interventions 
Among the 14 patients for whom ‘adherence’ 
interventions were recorded, the most common 
issue identified was patients’ difficulties in managing 
their medications (50.0% of patients), followed by 
patients’ poor understanding about their disease 
(35.7%) (Figure 2). A lack of belief that the 
medication would be helpful was an issue in only 1 
patient. The vast majority of adherence-based 
interventions comprised education and patient 
counselling; for the patients unable to manage their 
medications, interventions included strategies to act 
as ‘cues’ for remembering to take doses and dose 
administration aids.  
Therapeutic adjustment accounted for 
approximately 40% of all pharmacist interventions in 
both Groups B and C at the baseline visit. 
Recommendations for dosage changes were more 
commonly reported as part of initial visit: adding 
antihypertensive agents and changing to alternative 
antihypertensives were more often recommended in 
subsequent visits. In Group A only 5 changes were 
identified in the patients’ antihypertensive 
medication regimens over the 12-month study 
period, compared to 20 in Group B and 18 in Group 
C.  
Pharmacist feedback on service implementation  
Most pharmacists identified patient recruitment as 
the greatest difficulty encountered in 
implementation. Some pharmacists printed study 
leaflets/posters and set-up information tables to 
help promote the service and recruit more patients. 
Those who struggled to recruit patients cited the 
following reasons during the feedback: 
“It’s difficult to actually get someone to sign on the 
dotted line and it’s not necessarily because they 
were unwilling; I had people that were willing but 
didn’t meet the criteria.  The criteria was pretty 
tough” 
“…a lot of people simply didn’t come back for 
the second one regardless of phoning them or 
were just not willing to” 
“I took their blood pressure and it was really 
high ….. they don’t want to answer a 
questionnaire or they don’t want to come back 
in three months.” 
“…. patients were not prepared to commit to 
an ongoing process as required for the study” 
In Groups A and B, pharmacists reported that, in a 
number of cases, the patient’s BP improved from 
the initial screening assessment to the baseline 
Week 1 Visit (re-check of BP), which excluded them 
from further participation. Group C, the shorter 
intervention (without BP re-check after the initial 
screening) added later, avoided this issue. 
Pharmacists speculated on possible reasons for 
their observations: 
“Each time I’ve tested their blood pressure 
since [screening] it’s been fine.  Some of them 
have had changes in medications and they’ve 
increased or they’ve added another 
medication in like a calcium blocker.  A lot of 
them it was just about compliance at the 
beginning” 
Table 2. Group characteristics at time of recruitment 








(Short Pilot)  
(n=17) 
Age (mean ± SD) in years 71.6 ± 16.1 69.7 ± 13.2 59.1 ± 12.4 
Male   n  6 3 6 
Retired   n 8 8 9 
















Number of days per week they exercise >30 minutes  
(mean ± SD) 
3.6 ± 2.0 3.9 ± 2.6 3.7 ± 2.8 
Number of standard drinks of alcohol consumed per 
day   (mean ± SD) 
0.8 ± 1.1 0.8 ± 0.8 0.96 ± 1.06 
Medical conditions   n  
Diabetes 






































Years since hypertension diagnosis (mean ± SD) 13.0 ± 13.7 18.3 ± 17.0 9.3 ± 6.7 
SBP= systolic blood pressure; DBP = diastolic blood pressure; SD = standard deviation 
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DURATION OF PHARMACIST CONSULTATIONS 
Time (minutes): Screening (mean ± SD) 16.1 ± 2.7 14.1 ± 8.2 Not applicable 
Time (minutes): Visit – Baseline  (mean ± SD) 17.5 ± 2.9 24.3 ± 15.5 22.5 ± 6.0 
Time (minutes): Visit – 1 month (mean ± SD) Not applicable 13.5 ± 8.1 11.6 ± 3.8 
Time (minutes): Visit – 3 months  (mean ± SD) 18.8 ± 2.5 12.8 ± 3.7 11.3 ± 4.3 
Time (minutes): Visit – 12 months (mean ± SD) 17.5 ± 2.7 14.4 ± 3.2 Not applicable 
BLOOD PRESSURE (BP) 
BP (mmHg): Screening (mean ± SD) SBP: 147 ± 9 
DBP: 85 ± 12 
SBP: 153 ± 12 
DBP: 85 ± 11 
Not applicable 
BP (mmHg): Visit – Baseline (mean ± SD) SBP: 139 ± 8 
DBP: 82 ± 9 
SBP: 145 ± 19 
DBP: 81 ± 12 
SBP: 157 ± 14 
DBP: 92 ± 10 
BP (mmHg): Visit – 1 month (mean ± SD) Not applicable SBP: 139 ± 18 
DBP: 76 ± 13 
SBP: 141 ± 9 
DBP: 86 ± 11 
BP (mmHg): Visit – 3 months (mean ± SD) SBP: 132 ± 9 
DBP: 79 ± 8 
SBP: 137 ± 18 
DBP: 74 ± 12 
SBP: 132 ± 10 
DBP: 79 ± 8 
Change from Baseline to Visit – 3 months (Wilcoxon) SBP:   P=0.34 
DBP:  P=0.08 
SBP:   P=0.14 
DBP:  P=0.04 
SBP:   P<0.01 
DBP:  P<0.01 
BP (mmHg): Visit – 12 months (mean ± SD) SBP: 125 ± 9 
DBP: 75± 12 
SBP: 132 ± 14 
DBP: 73 ± 12 
Not applicable 
Change from Visit – 3 months to Visit – 12 months (Wilcoxon) SBP:   P=0.23 
DBP:  P=0.69 
SBP:   P=0.68 
DBP:  P=0.87 
Not applicable 
MEDICATION ADHERENCE 
MMAS*** Baseline  n (%) 
Low adherence (<6) 
Medium adherence (6 to <8) 













Visit – 3 months  n (%) 
Low adherence (<6) 
Medium adherence (6 to <8) 













Change from Baseline to Visit – 3 months (Pearson Chi-Square) P=0.62 P=0.19 P=0.01 
Visit – 12 months  n (%) 
Low adherence (<6) 
Medium adherence (6 to <8) 











Change from Visit –3 months to Visit –12 months (Pearson Chi-Square) P=0.81 P=0.68 Not applicable 
Median MMAS score: Visit – 1 month 7.82 ± 0.41 7.10 ± 1.73 6.06 ± 1.71 
Median MMAS score: Visit – 3 months 7.82 ± 0.60 7.20 ± 1.32 7.25 ± 0.93 
Change from Baseline to Visit – 3 months (Wilcoxon) P=1.00 P=1.00 P=0.004 
Median MMAS score: Visit –12 months 7.55 ± 0.93 7.33 ± 0.87 Not applicable 
Change from Visit – 3 months to Visit – 12 months (Wilcoxon) P=0.46 P=0.71 Not applicable 
QUALITY OF LIFE (QoL) 
EQ-5D-3L – INDEX values 







(0.68 - 1.00) 
0.70 
(0.61 – 1.00) 
0.71 
(0.62 – 1.00) 







(0.71 – 1.00) 
0.71 
(0.54 – 1.00) 
0.67 
(0.59 – 1.00) 
Change from Baseline to Visit – 3 months (Wilcoxon) P=0.66 P=0.79 P=0.91 







(0.63 – 1.00) 
0.78 
(0.46 – 1.00) 
Not applicable 
Change from Visit – 3 months to Visit – 12 months (Wilcoxon) P=0.58 P=1.00 Not applicable 
EQ VAS values 







(75.0 – 90.0) 
70.0 
(63.8 – 87.5) 
80.0 
(55.0 – 87.5) 







(80.0 – 93.0) 
80.0 
(67.5 – 85.0) 
74.0 
(60.0 – 84.3) 
Change from Baseline to Visit – 3 months (Wilcoxon) P=0.15 P=0.80 P=0.75 







(80.0 – 98.5) 
80.0 
(55.0 – 90.0) 
Not applicable 
Change from Visit – 3 months to Visit – 12 months (Wilcoxon) P=0.05 P=1.00 Not applicable 
SBP= systolic blood pressure; DBP = diastolic blood pressure; VAS = visual analogue scale; MMAS = Morisky Medication 
Adherence Scale; SD = Standard Deviation; *** Use of the ©MMAS is protected by US copyright laws. Permission for use is 
required. A license agreement is available from: Donald E. Morisky, ScD, ScM, MSPH, Professor, Department of Community 
Health Sciences, UCLA School of Public Health, 650 Charles E. Young Drive South, Los Angeles, CA 90095-17 
Bajorek B, LeMay KS, Magin P, Roberts C, Krass I, Armour CL. Implementation and evaluation of a pharmacist-led 
hypertension management service in primary care: outcomes and methodological challenges. Pharmacy Practice 
2016 Jan-Mar;14(2):723.  
doi: 10.18549/PharmPract.2016.02.723 
www.pharmacypractice.org      (eISSN: 1886-3655  ISSN: 1885-642X) 10 
“…With each one of them, compliance must have 
been an issue because each person came back 
apart from two of them, completely controlled the 
next week”. 
A couple of pharmacists commented on how time-
pressures had made it difficult to recruit since they 
were ‘not [always] the person - face-to-face - that 
[the patients] spoke to’ during that visit to the 
pharmacy, where other pharmacists and/or 
assistants may have been the primary contacts. 
This highlights the need for pharmacists to be able 
to commit sufficient time and effort to the chronic 
disease management program.  
Overview of the challenges in intervention 
implementation  
Synthesis of the study outcomes, participant 
feedback, and investigators’ reflections at the 
conclusion of the study, identified some key issues 
impacting on the actual implementation phase and 
program outcomes within the program evaluation 
framework (Table 1). Activities and actions in the 
‘pre-planning’ and ‘planning’ phases of the 
evaluation framework were identified as needing 
particular attention. First, the pharmacists’ restricted 
scope of practice, and an absence of well 
established relationships between some 
pharmacists and GPs, limited their ability to facilitate 
specific therapeutic interventions. Second, neither 
the pharmacists nor the investigators had 
conceptualised the initial screening step of the study 
(the initial BP checking step to identify poor BP 
control, prior to patient enrolment) as an 
intervention in its own right, and had 
underestimated the responsiveness of BP to 
changes in patient behaviour. Subsequently, 
pharmacists’ ability to recruit patients was affected 
(in following best practice guidelines for confirming 
uncontrolled BP), impacting on the overall sample 
size and power to identify significant differences in 
outcome measures between groups. Indeed, Group 
C was implemented within a modified study protocol 




Overall, this study has piloted a complex pharmacy-
based intervention to help optimise hypertension 
management in those with poor BP control, and has 
additionally highlighted some methodological 
challenges. In terms of key outcomes, changes 
were observed in Group C (i.e., shorter 
intervention), specifically a reduction in BP at the 3-
month visit, a significant improvement in medication 
adherence scores, and a trend to improvement in 
quality of life scores. In comparison, there were no 
significant changes in outcomes in Group B (full 
intervention), and no differences compared to 
Group A (usual care). Although the latter 
observations were perhaps disappointing, other 
studies exploring pharmacist-led interventions in 
chronic disease management (e.g., diabetes) have 
also shown no significant differences in outcomes 
between control and intervention groups.
42
  
Possible explanations for these observations 
include the critical difference between study groups, 
i.e., the initial BP screening step prior to service 
delivery. Group B required an initial BP ‘screening’ 
step, followed by a re-check of the BP 1-week later, 
consistent with guidelines.
20
 In contrast, Group C, 
patients were directly recruited after the initial BP 
assessment. The absence of this re-check step may 
explain key study observations. Pharmacists in 
Groups A and B expressed difficulties in recruiting 
patients; patients who were initially assessed as 
having elevated BP were 1-week later often re-
assessed as being within normal range, precluding 
their enrolment. While this, at face value, is simply 
an expression of the study inclusion/exclusion 
criteria, several pharmacists identified that the initial 
BP check prompted many patients into action (e.g., 
resuming their prescribed medications and/or 
consulting with GPs).  
Second, the impact of the initial BP measurement 
step on patients’ behaviours was also suggested by 
differences in mean BP readings between the study 
groups at baseline; the mean BPs reported at the 
re-check steps were slightly lower than initial 
readings, even in patients who were ultimately 
recruited to Group B. In Group C, the baseline BP 
readings were significantly higher than either Group 
A or B. While this may represent regression to the 
mean, our contextual information (pharmacists’ 
observations) suggests that the initial BP 
measurement step itself played a greater role than 
just procedural confirmation of hypertension prior to 
study enrolment, acting as an important intervention 
itself. Indeed, such so-called screening has been 
shown to effect behaviour change.
43
  
Third, the changes in outcomes observed in Group 
C may have been due to the absence of the BP re-
check step, thereby preventing patients from 
initiating behaviour changes prior to study 
enrolment. The net effect of this was higher mean 
BPs at baseline (and greater potential for 
demonstrating reduction in BP), and an increased 
opportunity to record patient-centred interventions 
as part of pharmacist recommendations (e.g., 
behaviour changes in relation to medication 
adherence, lifestyle measures) in Group C. The 
findings support this, given that adherence-based 
interventions were more common in Group C than 
in Group B. This highlights the potential impact of 
screening processes on prompting behaviour 
change in patients, at least in the short-term. 
These observations highlight the methodological 
challenges in evaluating interventions for 
hypertension management. Good clinical practice 
mandates that a diagnosis of hypertension is 
confirmed through repeated BP testing at 
designated intervals
20
; in applying these screening 
procedures, the diagnostic process may become a 
component of the intervention itself, thereby 
confounding study findings. At the first level the 
screening may have such a profound effect on 
potential participants that recruitment into studies 
becomes more difficult; secondarily, the impact of 
the screening and the components of the purpose-
designed intervention may become conflated. In this 
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study two intervention study groups were included 
to differentiate the potential impact of the screening 
step on process measures and patient outcomes, 
addressing this very issue.  
Additional methodological considerations relate to 
the ‘planning’ around study implementation, and 
more carefully exploring the local context. The 
current restrictions on Australian pharmacists’ 
scope of practice, suboptimal selection of 
geographical regions (i.e., with regard to access to 
health services), and lack of strong interprofessional 
relationships between some pharmacists and GPs, 
have limited the potential benefits afforded by this 
service model, compared to findings from other 
studies.
44
 These challenges aside, other potential 
study limitations must be acknowledged. This study 
was conducted in specific regions within Australia 
and may not be generalisable to other settings. The 
difficulties in recruiting patients may have under-
powered the study to detect significant changes in 
patient outcomes, and any changes observed in BP 
(Group C) may have been due to natural variations 
(regression to the mean), rather than the 
intervention. Furthermore, this study did not 
evaluate the characteristics of the participating 
pharmacists or pharmacies, and how these may 
have influenced any of the outcomes. A future 
larger scale study could address these limitations to 
provide more robust evidence for the impact of such 
an intervention. 
Overall, the within-group comparisons for the two 
interventions groups in this study have hinted at the 
potential benefits of a pharmacist-led hypertension 
management service beyond the initial 
measurement of BP and immediate improvement in 
adherence, including optimisation of therapy 
through therapeutic adjustment and persistence of 
adherence, to support GPs and patients alike. 
Although the methodological challenges and sample 
size limitations preclude a robust analysis of the key 
study outcomes (particularly in terms of between-
group comparisons), the results from this pilot study 
show that pharmacists have engaged in processes 
that can help monitor appropriate clinical 
parameters and identify appropriate strategies to 
optimise hypertension management in a step-wise 
approach, including generating recommendations 
for adjustment of therapeutic regimens that are 
acceptable to GPs. Previous studies have 
demonstrated the impact that pharmacists can have 
in improving hypertension management within 
community pharmacies
45
 or home-based monitoring 
services
46
, as well as in improving the quality of 
prescribing.
47
 Furthermore, this study specifically 
highlights what the critical components of such a 
service are, and how these can also present 
methodological challenges in the evaluation of 
services in this context. 
 
CONCLUSIONS 
A collaborative, pharmacist-led hypertension 
management service can help monitor BP, improve 
medication adherence, and optimise therapy in a 
step-wise approach. This study highlights the 
contribution of BP screening to effecting behaviour 
change in patients, particularly through adherence 
to medication. However, this can also present 
methodological challenges in the development and 
evaluation of services in this context, both in terms 
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